Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A picomolar inhibitor of the Plasmodium falciparum IPP pathway

Antimicrobial Agents and Chemotherapy(2024)10.1128/aac.01238-23Source: DataRank Database

A picomolar inhibitor of the Plasmodium falciparum IPP pathway is a research paper published in Antimicrobial Agents and Chemotherapy (2024). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

Linked data & code

bioproject

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 0.89)OA: hybridTopics (28)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Thomas Braukmann ORCID,Jon Doenier ORCID,Thomas R. Meister ORCID,Ellen Yeh ORCID,Stephanie Kabeche ORCID

Live enrichment

PubMed:39037239 PMC:PMC11304725 OpenAlex:https://openalex.org/W4400885680

HHS | NIH | National Institute of Allergy and Infectious Diseases

Grant: 1R01AI141366

HHS | National Institutes of Health

Grant: 5T32HG000044

NIAID NIH HHS

Grant: R01 AI141366

NHGRI NIH HHS

Grant: T32 HG000044

Chan Zuckerberg Initiative (CZI)

Wellcome Trust

Burroughs Wellcome Fund

Burroughs Wellcome Fund (BWF)

Chan Zuckerberg Initiative

Wellcome Trust

Burroughs Wellcome Fund (BWF)

Chan Zuckerberg Initiative (CZI)

FWCI

0.89

Citation Percentile

0.8%

Citation Trend

2024

2025

hybridLicense: other-oa

journalhttps://journals.asm.org/doi/pdf/10.1128/aac.01238-23?download=true

publisherhttps://journals.asm.org/doi/pdf/10.1128/aac.01238-23?download=true

publisherhttps://journals.asm.org/doi/pdf/10.1128/aac.01238-23

journalhttps://doi.org/10.1128/aac.01238-23

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39037239

Fields of Study

Malaria Research and ControlComputational Drug Discovery MethodsResearch on Leishmaniasis StudiesPlasmodium falciparumAntimalarialsOrganophosphorus CompoundsHemiterpenesDrug ResistanceHumansErythritol

MeSH Terms

AntimalarialsDrug ResistanceErythritolHumansOrganophosphorus CompoundsPlasmodium falciparumHemiterpenes

Keywords

Plasmodium falciparumPharmacologyChemistryBiologyMalariaImmunologydrug discoveryAntimalarial AgentsApicoplastMep PathwayIsoprenoid Biosythesis

Sustainable Development Goals

SDG 0: Good health and well-being

A picomolar inhibitor of the Plasmodium falciparum IPP pathway

FAIR Checklist

Authors (5)

Funding (12 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)